Idaptan (Trimetazidine Dihydrochloride)

Trimetazidine acts as a metabolic modulator. It blocks the mitochondrial enzyme responsible for fatty‑acid oxidation, shifting heart muscle metabolism toward glucose utilization. Glucose oxidation produces more energy per unit of oxygen, allowing the myocardium to function more efficiently during ischemic conditions.

The dosage of Idaptan is individualized by the prescribing physician based on the patient’s clinical condition, age, renal and hepatic function, and concomitant therapies. Healthcare professionals determine the appropriate strength and frequency according to current clinical guidelines.

Safety data for trimetazidine in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and this decision must be made by a qualified healthcare provider.

To request Idaptan, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Compared with agents such as ranolazine or traditional nitrates, trimetazidine does not significantly affect heart rate or blood pressure. Its primary advantage lies in metabolic modulation rather than vasodilation, making it useful when patients need additional symptom control without further lowering blood pressure.

Idaptan tablets should be stored at room temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep the container tightly closed and out of reach of children.

Idaptan is taken orally with a glass of water, usually with or without food as directed by the prescriber. The tablets should be swallowed whole and not crushed or chewed unless specifically instructed.

Serious adverse reactions, although rare, include Parkinsonian‑like movement disorders, severe hypotension, cardiac arrhythmias, hepatic dysfunction, anaphylaxis, and blood‑cell abnormalities such as neutropenia. Patients should seek immediate medical attention if they experience any of these symptoms.

Idaptan is contraindicated in patients with known hypersensitivity to trimetazidine or any tablet excipients, and it should be avoided in individuals with severe hepatic impairment, uncontrolled Parkinsonian syndromes, or those taking medications that may cause dangerous interactions as listed under major interactions.